At SEGOVA New Generation, our mission is to connect patients with leading European experts and evidence-based therapies in the field of regenerative reproductive medicine. A recently published scientific review entitled “Biologic Interventions in Menopausal Medicine: Endocrine and Reproductive Perspectives” highlights an evolution in how menopause and diminished ovarian reserve can be understood and potentially managed.
Traditionally, menopause has been defined as the permanent depletion of ovarian follicles, leading to infertility and hormonal decline. However, advances in regenerative medicine suggest that certain aspects of ovarian function may be improved through targeted biological therapeutic approaches.
What the Scientific Review Explores
The paper analyzes emerging regenerative strategies, including:
- High-concentration platelet-rich plasma (hcPRP)
- Therapies based on mesenchymal and hematopoietic stem cell–based therapies (MSC/HSC)
- In vitro maturation of oocytes (IVM)
- In vitro activation of ovarian tissue (IVA)
- Synergistic application of multiple stem cell types
- Subcellular exosomes
- Bioengineered scaffold (support) systems
Preclinical findings demonstrate biological effects such as activation of dormant follicles, improved estradiol production, and reduction of elevated follicle-stimulating hormone (FSH) levels. Early clinical data report measurable hormonal improvements, occasional restoration of menstrual cycles, and documented pregnancies in carefully selected patients previously considered infertile.
Importantly, the authors emphasize that despite promising mechanistic foundations and early results, large randomized clinical trials, GMP-compliant manufacturing standards, and strict ethical oversight are required before these interventions can become standard clinical practice.
Why This Matters for SEGOVA Patients
Within the SEGOVA program, we combine a fully individualized approach and detailed structural and functional diagnostics with innovative therapies applied responsibly and based on clear medical justification. We provide access to advanced ovarian regenerative therapies guided by a philosophy of continuously integrating the latest scientific insights into both diagnostics and treatment.
The concepts described in this publication align with our structured approach to ovarian rejuvenation programs, where therapy selection (PRP, stem cell-based therapies, or tissue-based strategies) is individualized according to ovarian reserve status and specific clinical indications.
Our role is to:
- Enable expert medical case review
- Coordinate diagnostics and specialist consultations
- Ensure transparent communication
- Safeguard ethical and medically justified application of regenerative options
Read the Full Scientific Publication
We encourage patients and colleagues to review the complete scientific publication for a deeper understanding of the biological mechanisms, current evidence, and future directions in regenerative menopausal medicine:
The original article is available at: https://www.sarjournal.org/abstractArticleContentBrowse/SAR/83/5/1/43392/abstractArticle/Article
